{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039782","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.427380+00:00","generated_at":"2026-06-12T01:58:07.766187+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Xenon appoints Dr. Gillian Cannon and Justin Gover to Board of Directors","bullets":["Dr. Cannon brings 30+ years of pharma experience; held senior roles at Merck, UCB, Otsuka, and Roivant.","Justin Gover was founding CEO of GW Pharma (sold for $7.2B) and led development of Epidiolex for epilepsy.","Appointments effective August 8, 2023; both will receive standard non-employee director compensation.","Their expertise aligns with Xenon's advancing XEN1101 in Phase 3 epilepsy trials and Phase 2 MDD study."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039782","json":"https://secwatch.observer/filing/0000950170-23-039782.json","markdown":"https://secwatch.observer/filing/0000950170-23-039782.md","text":"https://secwatch.observer/filing/0000950170-23-039782.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023039782/0000950170-23-039782-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023039782/xene-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:58:07.766187+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"af64ebed97","claim":"Mr. Justin Gover was appointed as director at Xenon Pharmaceuticals Inc..","evidence_excerpt":"appointed Dr. Gillian Cannon and Mr. Justin Gover as directors of the Company, effective as of August 8, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023039782/0000950170-23-039782-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"c60a763df6","claim":"Dr. Gillian Cannon was appointed as director at Xenon Pharmaceuticals Inc..","evidence_excerpt":"appointed Dr. Gillian Cannon and Mr. Justin Gover as directors of the Company, effective as of August 8, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023039782/0000950170-23-039782-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}